Disclosure of secondary findings in exome sequencing of 2480 Japanese cancer patients
暂无分享,去创建一个
K. Yamaguchi | T. Nagashima | M. Kusuhara | S. Nishimura | S. Ohnami | K. Urakami | H. Matsubayashi | M. Arai | Y. Kiyozumi | Y. Horiuchi | N. Kado | Satomi Higashigawa | Maki Mizuguchi | Makoto Arai
[1] T. Sugino,et al. Japanese version of The Cancer Genome Atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients , 2019, Cancer science.
[2] Lorenzo L. Pesce,et al. Pathogenic and Uncertain Genetic Variants Have Clinical Cardiac Correlates in Diverse Biobank Participants , 2019, bioRxiv.
[3] P. Butow,et al. Challenges and strategies proposed by genetic health professionals to assist with family communication , 2019, European Journal of Human Genetics.
[4] T. Aiba. Recent understanding of clinical sequencing and gene-based risk stratification in inherited primary arrhythmia syndrome. , 2019, Journal of cardiology.
[5] N. Spinner,et al. Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study , 2018, Genetics in Medicine.
[6] Y. Kamatani,et al. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls , 2018, Nature Communications.
[7] S. Richard,et al. Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations , 2018, European Journal of Human Genetics.
[8] K. Brothers,et al. Tensions in ethics and policy created by National Precision Medicine Programs , 2018, Human Genomics.
[9] K. Kinoshita,et al. Evaluation of reported pathogenic variants and their frequencies in a Japanese population based on a whole-genome reference panel of 2049 individuals , 2018, Journal of Human Genetics.
[10] A. Hozawa,et al. Population-based biobank participants’ preferences for receiving genetic test results , 2017, Journal of Human Genetics.
[11] Matthew S. Lebo,et al. A Model for Genome-First Care: Returning Secondary Genomic Findings to Participants and Their Healthcare Providers in a Large Research Cohort , 2017, bioRxiv.
[12] Y. Bang,et al. Findings of a 1303 Korean whole-exome sequencing study , 2017, Experimental &Molecular Medicine.
[13] K. Offit,et al. Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling. , 2017, Journal of oncology practice.
[14] Marylyn D. Ritchie,et al. Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study , 2016, Science.
[15] K. Yamaguchi,et al. Integrated next-generation sequencing analysis of whole exome and 409 cancer-related genes. , 2016, Biomedical research.
[16] K. Yamaguchi,et al. Optimizing an ion semiconductor sequencing data analysis method to identify somatic mutations in the genomes of cancer cells in clinical tissue samples. , 2016, Biomedical research.
[17] W. Chung,et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.
[18] Joshua L. Deignan,et al. A survey of current practices for genomic sequencing test interpretation and reporting processes in US laboratories , 2016, Genetics in Medicine.
[19] M. Dwyer,et al. Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[20] Y. Miki,et al. Prevalence and differentiation of hereditary breast and ovarian cancers in Japan , 2015, Breast Cancer.
[21] Sarah M. Hartz,et al. Identification of Medically Actionable Secondary Findings in the 1000 Genomes , 2015, PloS one.
[22] G. Petersen,et al. Preferences regarding Return of Genomic Results to Relatives of Research Participants, Including after Participant Death: Empirical Results from a Cancer Biobank , 2015, Journal of Law, Medicine & Ethics.
[23] Bartha Maria Knoppers,et al. Return of genetic testing results in the era of whole-genome sequencing , 2015, Nature Reviews Genetics.
[24] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[25] Jennifer B. McCormick,et al. Patients' views on incidental findings from clinical exome sequencing , 2015, Applied & translational genomics.
[26] D. Valle,et al. Assessment of incidental findings in 232 whole exome sequences from the Baylor-Hopkins Center for Mendelian Genomics , 2014, Genetics in Medicine.
[27] T. Nakajima,et al. Implementation of individualized medicine for cancer patients by multiomics-based analyses—the Project HOPE—. , 2014, Biomedical research.
[28] Deanna M. Church,et al. ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..
[29] E. Palmaer,et al. Patient decisions for disclosure of secondary findings among the first 200 individuals undergoing clinical diagnostic exome sequencing , 2013, Genetics in Medicine.
[30] B. Knoppers,et al. Recommendations for returning genomic incidental findings? We need to talk! , 2013, Genetics in Medicine.
[31] Marc S. Williams,et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.
[32] Larry N. Singh,et al. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. , 2012, American journal of human genetics.
[33] Pablo Cingolani,et al. © 2012 Landes Bioscience. Do not distribute. , 2022 .
[34] M. Isobe,et al. Prevalence and distribution of sarcomeric gene mutations in Japanese patients with familial hypertrophic cardiomyopathy. , 2012, Circulation journal : official journal of the Japanese Circulation Society.
[35] Matthew Mort,et al. The Human Gene Mutation Database: providing a comprehensive central mutation database for molecular diagnostics and personalised genomics , 2009, Human Genomics.
[36] T. Iwama,et al. Mechanism of carcinogenesis in familial tumors , 2004, International Journal of Clinical Oncology.
[37] N. Gruis,et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16‐Leiden) , 2000, International journal of cancer.
[38] P. Sham,et al. Actionable secondary findings from whole-genome sequencing of 954 East Asians , 2017, Human Genetics.
[39] JCSJointWorkingGroup. Guidelines for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (JCS 2012) - Digest Version . , 2016, Circulation journal : official journal of the Japanese Circulation Society.